Celgene生物制藥公司

排名：第57位

連續(xù)在榜年數(shù)：3年

????這家生物制藥公司去年進(jìn)行了兩筆重大并購——買下了制藥公司Gloucester和生物技術(shù)公司Abraxis——以推進(jìn)其成為腫瘤治療領(lǐng)域領(lǐng)導(dǎo)者的目標(biāo)。在國際擴(kuò)張、銷售增長和近期并購等因素助力下，該公司今年銷售收入增長9.359億美元，達(dá)到36億美元。

????2009年，藥物薩力多胺（Thalidomide，一種安眠藥，鎮(zhèn)靜劑——譯注）大獲成功，Celgene公司首度登上本榜單，排在第22位。該藥此前曾因會引起先天畸型而遭禁，但此后即改變用途，成為多發(fā)性骨髓瘤的特效藥?，F(xiàn)在，公司可以靠雷利米得（Revlimid）和阿扎胞苷（Vidaza，治療血液和骨髓疾病）來獲得銷售收入的持續(xù)增長。

Celgene

100 Fastest-Growing Rank: 57

Consecutive years on the list: 3

????The biopharmaceutical company made two major acquisitions last year -- the pharmaceutical company Gloucester and biotech firm Abraxis -- to advance its goal of becoming an oncology leader. Revenues this year grew by $935.9 million to hit $3.6 billion, aided by the company's international expansion, sales growth, and its newly acquired companies.

????Celgene made its debut on Fortune's Fastest-Growing Companies list in 2009 at No. 22, riding on the success of its drug Thalidomide, which was previously shunned for causing birth defects but was repurposed as a treatment for multiple myeloma. It now can credit drugs Revlimid and Vidaza (for blood and bone marrow conditions) for its continued growth in revenues.